The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The DMOAD Dream a Generation Later

The DMOAD Dream a Generation Later

March 18, 2011 • By Jean-Pierre Pelletier, MD, and Johanne Martel-Pelletier, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions
  • Knee Injuries Associated with Accelerated Knee Osteoarthritis
  • Rheumatology Coding Corner Answer: Coding for a Knee Injection
Explore This Issue
March 2011
click for large version

There is no doubt that the management of symptoms and pain associated with OA needs to be studied more thoroughly. Not only should we better understand the mechanisms of such symptoms but also, as recently proposed, we should “think outside the joint.”13 Recent findings indicate that neuropathic pain may contribute substantially to OA disease symptoms in a significant number of patients.14 The thinking surrounding the treatment of OA may be somewhat too focused on pain, a subjective symptom that may originate from many sources, particularly in elderly patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ultimate vision for the treatment of OA has been to find agents that can reduce or stop the progression of the disease. Thus far, no such treatment has been approved by regulatory authorities as meeting the appropriate guidelines and criteria. However, a number of drugs and agents, including doxycycline, chondroitin sulfate, and glucosamine sulfate have been demonstrated by X-ray to effectively reduce joint space narrowing in patients with knee OA; of note, licofelone has been shown by magnetic resonance imaging (MRI) to decrease cartilage volume loss.15-20 Moreover, diacerein was shown to reduce the progression of hip OA.21 However, disagreement over the interpretation of the results of some of these studies is notable and pertains to issues regarding sample size, sensitivity and reliability of imaging technology used, and the patient population studied.22,23

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version

DMOAD Development Is a Risky Business for Many

Major hurdles are responsible for the limited effort to develop new disease-modifying OA drugs (DMOADs). These hurdles can be explained quite simply by two major factors that are intertwined. The first is the key basis for the development of DMOADs, which is financial support from industry. Second is the regulatory environment that provides guidelines for the development of DMOADs.24,25 The research and development programs for DMOADs are very costly; to many investigators in the field, the regulations seem outdated, making it a high-risk investment for the industry. The perception of the current regulatory guidelines on DMOAD development is that they do not provide updated and optimal guidance and, very importantly, that key elements of these guidelines do not incorporate recent advances in the field of OA research. These advances could significantly impact study design and conduct (see Table 1). We can only hope that recent initiatives to open the dialogue for discussion with regulatory agencies will be successful at resolving these issues.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Osteoarthritis Tagged With: Diagnostic Criteria, Drugs, Osteoarthritis, patient care, Research, TreatmentIssue: March 2011

You Might Also Like:
  • New Research Shows Chondroitin Sulphate Reduces Cartilage Volume Loss, Bone Marrow Lesions
  • Knee Injuries Associated with Accelerated Knee Osteoarthritis
  • Rheumatology Coding Corner Answer: Coding for a Knee Injection
  • Rheumatology Coding Corner Answer: Coding for a Knee Injection

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.